CCIPD’s Anant Madabhushi, PhD, and Pranjal Vaidya with collaborators Kaustav Bera, MD, and Vamsidhar Velcheti, MD, have been awarded US Patent #10,839,513, “Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features.” Shortly following this award, CCIPD researchers were also awarded US Patent #10,846,367, ”Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic features.” CCIPD co-inventors for this patent include Anant Madabhushi, PhD, Xiangxue Wang, PhD, and Pranjal Vaidya. These two patents have brought the CCIPD patent portfolio to a total of 60 awarded patents.
